

Low-Dose Naltrexone Primer

A Clinical Guide to Optimizing LDN Therapy

Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine

Integrative & Functional Medicine Physician
University of Arizona Integrative Medicine Fellowship Graduate
Institute of Functional Medicine Scholarship Recipient

Low-dose naltrexone (LDN) has emerged as a promising therapeutic option for numerous chronic conditions, from fibromyalgia and chronic pain to autoimmune disorders and mast cell activation syndrome. As a physician who has been prescribing LDN for over two decades and has presented at multiple LDN Research Trust conferences, I have witnessed its remarkable benefits in many patients. However, I have also observed a clinical reality that warrants honest discussion: approximately one-third of patients do not respond to standard LDN therapy. Understanding why LDN fails—and what to do about it—is crucial for folks seeking to optimize outcomes.

Low Dose Naltrexone Support Group

www.ldnsupportgroup.org
\$10 | 2025 Edition

Understanding the LDN Response Spectrum

Published literature shows response rates typically ranging from 57-65% in various chronic pain populations. In clinical experience, patients fall into three distinct categories when it comes to LDN therapy.

Category 1: LDN as Sufficient Therapy

For some patients, LDN alone produces profound and sustained improvement. These patients typically have adequate baseline endorphin reserves, moderate disease severity, conditions primarily driven by neuroinflammation or immune dysregulation, and good overall functional capacity.

Research supports that LDN can be highly effective as monotherapy in conditions like fibromyalgia, where studies have demonstrated a 28.8% reduction in pain compared to 18% with placebo. A retrospective analysis from Mayo Clinic found that 65% of patients taking LDN for chronic pain reported perceived benefit.

Category 2: LDN as Necessary but Not Sufficient

In complex cases, LDN plays a vital role but cannot achieve remission on its own. These conditions include mold toxicity and chronic inflammatory response syndrome (CIRS), cancer, mast cell activation syndrome (MCAS), Long COVID, complex regional pain syndrome (CRPS), and chronic Lyme disease.

For these patients, LDN serves as one critical component of a multimodal treatment strategy. LDN does not target the root cause directly but can calm the immune system enough to make deeper treatment more successful and better tolerated.

Category 3: Non-Responders

Some patients simply do not respond to LDN at any dose. This may relate to severely depleted endorphin reserves, genetic variations in opioid receptor function, conditions not primarily mediated by the pathways LDN modulates, or co-existing factors that override LDN's mechanisms.

The Clinical Approach: Assessing Endorphin Reserve

The clinical approach begins with estimating a patient's endorphin reserve by assessing their functional capacity in everyday life. This concept is fundamental to personalizing LDN therapy.

Assessment Questions to Consider

- **Duration of illness:** How long have they been sick?
- **Sleep quality:** Do they achieve restorative sleep?
- **Energy levels:** What is their baseline energy throughout the day?
- **Resilience:** How quickly do they recover from setbacks?
- **Functional capacity:** Can they work, exercise, or perform daily activities?

Patients with severely depleted endorphin reserves—those who are very ill or have very low functional capacity—require a different approach than the standard 1.5 mg to 4.5 mg dosing.

Dosing Strategies for Challenging Cases

Starting Low: Microgram Dosing

For patients who are very ill, have low functional capacity, or are children, starting at significantly lower doses than the conventional 1.5-4.5 mg range is recommended. This approach is sometimes called ultra-low-dose naltrexone (ULDN) or very-low-dose naltrexone (VLDN).

The LDN Research Trust's dosing guidelines recognize three categories:

- **Ultra-low dose:** Microgram dosing (1-2 mcg)
- **Very-low dose:** 0.01-0.5 mg daily
- **Low dose:** 1-4.5 mg (sometimes up to 10 mg)

At 1 microgram, naltrexone binds to opioid receptors but is not likely to overwhelm the system, potentially acting as a weak agonist through the phenomenon of hormesis—where a substance acts as an inhibitor at high concentrations but as a stimulator at lower concentrations.

The Nanogram Option

For patients who cannot tolerate even microgram doses, there are options to dilute further to nanogram ranges. These preparations are not typically available from pharmacies and require specialized compounding or self-dilution protocols. While clinical evidence at this dose range is limited, some highly sensitive patients have reported benefit.

Titration Protocol for Sensitive Patients

For sensitive patients, start at 0.5-1 mg (or lower if indicated) and increase slowly over extended periods. Some patients may need 2-week intervals between dose increases, others may require 4-week intervals, and the most sensitive patients may need 3-month intervals between adjustments. This contrasts with typical protocols that escalate to 4.5 mg within 2-4 weeks. Patience is essential.

When Standard LDN Fails: Alternative Strategies

Strategy 1: Higher-Dose Naltrexone for Neuropathy

If there is no response to standard LDN dosing, especially in neuropathic pain conditions, consider adding ketosis support (ketogenic diet over exogenous ketones), increasing the dose to 25 mg or even up to 45 mg, and using other supplements.

This higher-dose approach moves into "moderate-dose" territory and may work through different mechanisms than traditional LDN. A dose-response study found that the effective dose in 95% of fibromyalgia patients (ED95) was 5.40 mg, with some patients benefiting from doses up to 6 mg. However, clinical experience suggests some neuropathy patients respond to even higher doses.

The rationale for combining with ketosis relates to the metabolic and anti-inflammatory effects of ketone bodies, which may synergize with naltrexone's mechanisms in neuropathic conditions.

Strategy 2: MCAS Protocol Enhancement

For complex conditions like mast cell activation syndrome (MCAS), consider adding ketotifen (1-2 mg at bedtime, increasing as tolerated), cromolyn sodium (mast cell stabilizer), and methylene blue combined with ketosis.

The Role of Ketotifen and Cromolyn: Ketotifen is an oral mast cell stabilizer that inhibits the release of histamine, tryptase, and various prostaglandins from mast cells. It reduces antigen-induced mast cell degranulation and stabilizes calcium permeability in mast cell membranes. Combined with cromolyn sodium, which works by inhibiting immediate and late-phase mast cell release, these medications can significantly improve MCAS symptoms including urticaria, nausea, diarrhea, and neurological manifestations.

Methylene Blue and Mitochondrial Support: Methylene blue has gained attention for its ability to enhance mitochondrial function by acting as an alternative electron carrier in the electron transport chain. It can increase ATP production, reduce oxidative stress, and decrease neuroinflammation. For patients with chronic fatigue, MCAS, or conditions involving mitochondrial dysfunction, methylene blue combined with ketosis may provide synergistic benefits that support overall healing alongside LDN.

Practical Recommendations Summary

Clinical Scenario	Recommended Approach
Standard patient, moderate illness	Start 1.5 mg, titrate to 4.5 mg over 2-4 weeks
Severely ill / low functional capacity	Start 0.5 mg or lower; titrate every 2-4 weeks
Children	Microgram dosing; very slow titration
Extreme sensitivity	Consider nanogram ranges; titrate every 1-3 months
Side effects at low doses	Drop to lower dose; slower titration
Non-response in neuropathy	Consider higher doses (up to 25-45 mg) + ketosis
Complex MCAS	Add ketotifen, cromolyn; consider methylene blue + ketosis
Treatment-resistant cases	Comprehensive functional medicine workup

Conclusion

LDN is a powerful tool in the integrative medicine toolkit, but it is not a universal solution. Approximately one-third of patients will not respond to standard protocols, and recognizing this reality is the first step toward better outcomes. By carefully assessing each patient's endorphin reserve, tailoring dosing strategies, and integrating complementary approaches when needed, we can optimize results and offer hope even to patients with treatment-resistant conditions.

The key is individualization. There is no one-size-fits-all approach to LDN therapy. Whether it means starting at microgram doses for the severely depleted patient or pushing to higher doses for refractory neuropathy, the clinician must be willing to think beyond standard protocols while remaining grounded in the science.

For patients struggling with complex chronic conditions, working with a physician experienced in LDN and functional medicine can make the difference between treatment failure and meaningful improvement.

About the Author

Yoon Hang Kim, MD, MPH is a board-certified physician specializing in integrative and functional medicine. A graduate of Dr. Andrew Weil's Integrative Medicine Fellowship at the University of Arizona, Dr. Kim has been practicing integrative medicine since 1999. He is recognized internationally as an expert in LDN therapy, having authored two books on LDN and published articles on chronic pain management. Dr. Kim has presented at multiple LDN Research Trust conferences and provides guest podcast appearances on LDN topics.

Dr. Kim practices virtual telemedicine through Direct Integrative Care, serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas.

Clinical Services: www.directintegrativecare.com

Educational Services: www.yoonhangkim.com

Additional Resources

- Direct Integrative Care Blog: directintegrativecare.com/integrative-medicine-blog
- Dr. Kim's YouTube Channel: youtube.com/@YoonHangKimMD
- LDN Support Group: ldnsupportgroup.org

References

Bruun KD, Christensen R, Amris K, et al. Low-dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial. *Trials*. 2021;22(1):804.

Kim YH. Ultra low dose naltrexone, micro dosing [Conference presentation]. LDN Research Trust 2018 Conference.

LDN Research Trust. Dosing information for prescribers. 2024.

Rosenberg S. Ketotifen: How it works and its uses in your practice. Oregon Association of Naturopathic Physicians. 2022.

Toljan K, Vrooman B. Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions. *Biomedicines*. 2023;11(4):1087.

Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. *BMJ Case Reports*. 2018;bcr2017221405.

Yang SH, Li W, Sumien N, et al. Mitochondria as a target for neuroprotection: Role of methylene blue and photobiomodulation. *Transl Neurodegener*. 2017;9(1):19.

Yang J, Shin KM, Do A, et al. The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: A systematic review. *J Pain Res*. 2023;16:1017-1023.

Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. *Arthritis Rheum*. 2013;65(2):529-538.

Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. *Clin Rheumatol*. 2014;33(4):451-459.

Disclaimer: This publication is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting or modifying any treatment regimen.

© 2025 Yoon Hang Kim, MD, MPH | LDN Support Group

All rights reserved. This material is provided for personal use only. No part may be reproduced, distributed, or transmitted without prior written permission from the author."

www.ldnsupportgroup.org